Companies › Tectonic Therapeutic
1 active drug program in 1 registered trial: 1 Phase 2; Cardiovascular; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TX000045 | – | Phase 2 | Pulmonary Hypertension | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06616974 | TX000045 | Phase 2 | Pulmonary Hypertension | Cardiovascular | Nov 2026 |
Cash of $235m on 2026-09-30; operating cash outflow about $73m a year; runway about 38 months at that burn, to Dec 2029; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Thryv Therapeutics Kardigan Kiniksa Pharmaceuticals International Nyrada AllRock Bio
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.